The association between sodium–glucose cotransporter 2 inhibitors and contrast-associated acute kidney injury in patients with type 2 diabetes undergoing angiography: a propensity-matched study
Authors:
Open Access
- 24 December 2024
- journal article
- research article
- Published by Springer Nature in European Journal of Medical Research
- Vol. 29 (1) , 1-11
Abstract
Sodium–glucose cotransporter-2 inhibitors (SGLT2i) have been proven to prevent decline in kidney function and failure. Whether SGLT2i affect the risk of contrast-associated acute kidney injury (CA-AKI) remains uncertain. Use of SGLT2i was assessed in consecutive diabetics undergoing coronary angiography (CA) or percutaneous coronary intervention (PCI) from January 2020 to May 2023 at a tertiary hospital in Chongqing, China. Propensity-matched analysis was used to adjust for baseline variables. CA-AKI was defined by the Acute Kidney Injury Network (AKIN) as creatinine increase ≥ 0.3 mg/dl (26.4 μmol/l), or a percentage increase in the serum creatinine level of ≥ 50%. A total of 604 new users of SGLT2i, and 298 chronic users of SGLT2i were matched with non-users. New use of SGLT2i was not associated with an increased incidence of AKIN-defined CA-AKI (OR 1.60; 95% CI 0.97–2.63; p = 0.065), in-hospital new-onset dialysis (OR 0.50; 95% CI 0.09–2.73; p = 0.422), or death (OR 0.55; 95% CI 0.18–1.66; p = 0.289). However, it was associated with a minor (> 25%) creatinine elevation (OR 1.55; 95% CI 1.04–2.30; p = 0.030), a 0.3 mg/dl increase in creatinine (OR 1.66; 95% CI 1.01–2.75; p = 0.048), and CMSC-defined CA-AKI (OR 1.51; 95% CI 1.02–2.24; p = 0.039). By 90 days, there was no evidence creatinine elevation differed between the two groups (p = 0.590). Chronic use of SGLT2i was not associated with AKIN-defined CA-AKI (OR, 0.92; 95% CI 0.41–2.05; p = 0.838). New use of SGLT2i during CA or PCI was not associated with an AKIN-defined CA-AKI, and it did not translate into new-onset dialysis or death during hospital stay. Chronic usage of SGLT2i did not affect creatinine. Further randomized clinical trials are warranted to confirm this finding. What was known: Sodium–glucose cotransporter-2 inhibitors (SGLT2i) have a renal protective effect; however, they cause an acute increase in the creatinine level and dip in glomerular filtration rate (GFR) upon treatment initiation. This study adds: New use of SGLT2i during coronary angiography or percutaneous coronary intervention was associated with an acute increase in the creatinine level, but it did not translate into new-onset dialysis or death during hospital stay, causing a pseudo contrast-associated acute kidney injury, and the creatinine level seemed return to normal thereafter. Continuation of SGLT2i did not affect creatinine elevation. Potential impact: Usage of SGLT2i may be safe during coronary angiography or percutaneous coronary intervention. Randomized controlled trials and other observational studies are needed to validate our observation.Keywords
This publication has 38 references indexed in Scilit:
- Renal Protection with SGLT2 Inhibitors: Effects in Acute and Chronic Kidney DiseaseCurrent Diabetes Reports, 2022
- Effects of canagliflozin compared with placebo on major adverse cardiovascular and kidney events in patient groups with different baseline levels of HbA1c, disease duration and treatment intensity: results from the CANVAS ProgramDiabetologia, 2021
- Effects of the SGLT2 inhibitor canagliflozin on plasma biomarkers TNFR-1, TNFR-2 and KIM-1 in the CANVAS trialDiabetologia, 2021
- Current Risk of Contrast-Induced Acute Kidney Injury After Coronary Angiography and Intervention: A Reappraisal of the LiteratureCanadian Journal of Cardiology, 2017
- Coronary Catheterization and Percutaneous Coronary Intervention in ChinaJAMA Internal Medicine, 2016
- Contrast induced nephropathy: updated ESUR Contrast Media Safety Committee guidelinesEuropean Radiology, 2011
- Risk of contrast-medium-induced nephropathy in high-risk patients undergoing MDCT – A pooled analysis of two randomized trialsEuropean Radiology, 2008
- Contrast-Induced Acute Kidney InjuryJACC, 2008
- Fenoldopam Mesylate for the Prevention of Contrast-Induced NephropathyJAMA, 2003
- Contrast-media-induced nephrotoxicity: a consensus reportEuropean Radiology, 1999